作者:Yifan Sun, Haihua Long, Lin Sun, Xiujuan Sun, Liping Pang, Jianlin Chen, Qingqun Yi, Tianwei Liang and Yongqi Shen
单位:柳州市柳铁中心医院
期刊:Cancer Cell International
活动价:
市场价:¥1200.00
CL0197
DMEM+10%FBS+1%P/S
LoVo
上皮细胞样
90%FBS+10%DMSO
LOVO
DMEM+10%FBS+1%P/S
贴壁
每周2~3次
BSL-1
人源
结肠
结肠腺癌IV级,Dukes'typeC
56岁男性
LOVO细胞系来源于IV级DukeC型结肠腺癌,其特征是腺瘤性息肉病大肠杆菌(APC)基因、Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)和肿瘤蛋白p53(TP53)突变。这些遗传特征有助于研究结直肠癌进展、转移和耐药机制的分子基础。
G6PD,B,PGM1,2,PGM3,1-2,6PGD,A,ES-D,1
carcinoembryonicantigen(CEA)908ng/106cells/10days
myc+、myb+、ras+、fos+、p53+、sis-、abl-、ros-、src
裸鼠
HLA A11,B15,B17,Cw1,Cw3,blood type B
携带Kras基因密码子13突变:GGC(WtGly)>GAC(Asp)
阴性
LoVo(人结肠癌)
复苏或冻存细胞到货处理方式LoVo(人结肠癌)
培养操作步骤LoVo(人结肠癌)
售后条例| Amelogenin | X,Y |
| CSF1PO | 10,11,13,14 (AddexBio=C0009011/380; CCRID; CLS=300266; PubMed=25877200) 10,14 (KCLB=10229) 11,12,13 (RCB=RCB1639) 11,12,13,14,15 (DSMZ=ACC-350) 11,13,14 (ATCC=CCL-229; ECACC=87060101; JCRB=IFO50067; JCRB=JCRB9083; PubMed=25926053) 11,14 (Cosmic-CLP=907790) |
| D2S1338 | 16,17,18 (DSMZ=ACC-350; PubMed=15771911) 17,18 (ATCC=CCL-229; CCRID; PubMed=25877200) |
| D3S1358 | 14,15,16,17 (ATCC=CCL-229) 14,16 (PubMed=15771911) 14,16,17,18 (CCRID) 14,16,17 (DSMZ=ACC-350) 14,17 (PubMed=25877200_130903) 14,18 (KCLB=10229; PubMed=25877200_584429) |
| D5S818 | 11,12,13 (AddexBio=C0009011/380; ATCC=CCL-229; DSMZ=ACC-350; JCRB=IFO50067; JCRB=JCRB9083; PubMed=25926053; RCB=RCB1639) 11,13 (CCRID; CLS=300266; Cosmic-CLP=907790; ECACC=87060101; KCLB=10229; PubMed=25877200) |
| D7S820 | 9.3,10,11 (AddexBio=C0009011/380; ATCC=CCL-229; CCRID; DSMZ=ACC-350; JCRB=IFO50067; PubMed=25877200; PubMed=25926053) 10,11 (CLS=300266; Cosmic-CLP=907790; ECACC=87060101; JCRB=JCRB9083; KCLB=10229; RCB=RCB1639) |
| D8S1179 | 9,10 (DSMZ=ACC-350; PubMed=15771911) 10 (ATCC=CCL-229; CCRID; PubMed=25877200) |
| D13S317 | 8,11 |
| D16S539 | 9,11,12 (DSMZ=ACC-350) 9,12 (AddexBio=C0009011/380; ATCC=CCL-229; CCRID; CLS=300266; Cosmic-CLP=907790; ECACC=87060101; JCRB=IFO50067; JCRB=JCRB9083; PubMed=15771911; PubMed=25877200; PubMed=25926053; RCB=RCB1639) |
| D18S51 | 13,17,18 (DSMZ=ACC-350; PubMed=11416159) 13,18 (ATCC=CCL-229; CCRID; CLS=300266; PubMed=15771911; PubMed=25877200) |
| D19S433 | 14,15 (ATCC=CCL-229; CCRID; DSMZ=ACC-350; PubMed=25877200) 15 (PubMed=15771911) |
| D21S11 | 29,31.2 (ATCC=CCL-229; CCRID; DSMZ=ACC-350; PubMed=15771911; PubMed=25877200; PubMed=25926053) 29,31.2,32.2 (CLS=300266) |
| FGA | 18,19,20 (DSMZ=ACC-350; PubMed=15771911) 18,20 (ATCC=CCL-229; CCRID; CLS=300266; PubMed=11416159; PubMed=25877200) |
| Penta D | 9,10,14 (CLS=300266) 10,14 (ATCC=CCL-229; DSMZ=ACC-350; PubMed=25877200) |
| Penta E | 9,16 (DSMZ=ACC-350) 10,16 (ATCC=CCL-229; CLS=300266; PubMed=25877200) |
| SE33 | 19.2,20.2,25.2 |
| TH01 | 9.3 |
| TPOX | 8,9 |
| vWA | 16,17,18,19 (DSMZ=ACC-350) 17,18 (AddexBio=C0009011/380; ATCC=CCL-229; CCRID; CLS=300266; Cosmic-CLP=907790; ECACC=87060101; JCRB=IFO50067; JCRB=JCRB9083; KCLB=10229; PubMed=11416159; PubMed=25877200; PubMed=25926053; RCB=RCB1639) 17,19 (PubMed=15771911) |


IF
作者:Yifan Sun, Haihua Long, Lin Sun, Xiujuan Sun, Liping Pang, Jianlin Chen, Qingqun Yi, Tianwei Liang and Yongqi Shen
单位:柳州市柳铁中心医院
期刊:Cancer Cell International